Clinical trials: Malignant Tumor With Metastasis
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors
RATIONALE: Stereotactic radiosurgery delivers x-rays directly to the tumor and may cause less damage to normal tissue. PURPOSE: Phase II trial to study the effectiveness of stereotactic radiosurgery in treating patients who have…
- Trial name
- NCT00006456
- Testing
- stereotactic radiosurgery
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Virginia Commonwealth University
Leukemia, Lymphoma
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of perifosine in treating patients who have refractory…
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00019656
- Testing
- perifosine
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
This randomized phase III trial studies carboplatin, paclitaxel and gemcitabine hydrochloride when given together with or without bevacizumab after surgery to see how well it works in treating patients with ovarian, epithelial…
- Conditions
- Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
- Trial name
- NCT00565851
- Testing
- Bevacizumab, Carboplatin, Docetaxel
- Where
- 709 sites in United States, Japan and 1 more
- Volunteers
- 1,052 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor
This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors
This is a first-in-human Phase 1, single-arm, open-label, multicenter, multiple-dose, dose-escalation and dose-expansion study of ABL503 to evaluate the safety, tolerability, MTD and/or RP2D, PK, immunogenicity, preliminary…
- Trial name
- NCT04762641
- Testing
- ABL503
- Where
- 8 sites in United States, South Korea
- Volunteers
- 100 people
- Sponsor
- ABL Bio, Inc.
Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma
Testing the Safety of CB-5339 in Patients With Cancer
This phase I trial studies the side effects and best dose of CB-5339 in treating patients with solid tumors that has spread to other places in the body (advanced) or lymphomas.
- Conditions
- Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT04372641
- Testing
- p97 Inhibitor CB-5339 Tosylate
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Stromal Tumors
Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK
In patients who are receiving nilotinib, nilotinib plasma levels will be measured after 1 month of nilotinib treatment. The relationship between surgery type and nilotinib pharmakokinetic properties will be investigated in this…
- Trial name
- NCT00976612
- Testing
- Nilotinib
- Where
- South Korea
- Volunteers
- 17 people
- Sponsor
- Asan Medical Center
NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
This is a multicenter, open-label, randomized (1:1) trial designed to evaluate whether ctDNA-guided interruption of immune-checkpoint inhibitor (ICI) therapy provides comparable survival to standard of care (SoC) continuous ICI…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLC
- Trial name
- SIGNAL-IO 301 (NCT07689812)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 920 people
- Sponsor
- Natera, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JBI-802 in patients with Advanced Solid Tumors.The efficacy of the RP2D will be evaluated in phase 2 in patients…
- Trial name
- NCT05268666
- Testing
- JBI-802
- Where
- 4 sites in United States
- Volunteers
- 126 people
- Sponsor
- Jubilant Therapeutics Inc.
Refractory Metastatic Colorectal Cancer, Solid Tumor
Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers
This Phase Ib/IIa study comprises a Main Study and a Study Extension. The Main Study has been designed according to a 3+3 Dose Escalation/dose Expansion design in refractory pMMR-MSS mCRC patients.
- Conditions
- Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer, Mismatch Repair Protein Proficient
- Trial name
- NCT05205330
- Testing
- CR6086, AGEN2034
- Where
- 3 sites in Italy
- Volunteers
- 107 people
- Sponsor
- Rottapharm Biotech
Glioblastoma, Brain Metastases
PET/CT Imaging of Malignant Brain Tumors With 124I-NM404
The purpose of this study is to evaluate diagnostic imaging techniques using 124I-NM404 PET/CT in humans with brain metastases and GBMs.
- Trial name
- NCT01516905
- Testing
- NM404
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Wisconsin, Madison
Colorectal Cancer, Liver Metastases
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
Background: Many people with colorectal cancer get liver metastases. Standard treatment for this is a combination of chemotherapy drugs. Directing the chemotherapy to the liver may be effective.
- Conditions
- Colorectal Cancer, Liver Metastases, Colorectal Adenocarcinoma, Colorectal Cancer With Hepatic Metastases
- Trial name
- NCT03366155
- Testing
- Codman 3000 constant flow pump catheter, Panitumumab, FUDR-Dex
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer
RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00084513
- Testing
- trastuzumab, imatinib mesylate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Fox Chase Cancer Center
Brain Metastases From Solid Tumors
131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors
The aim of this Proof of Concept study is to determine the therapeutic potential of the L19SIP antibody, labeled with the radionuclide 131I in combination with external beam radiation, for the treatment of patients with multiple…
- Trial name
- NCT01125085
- Testing
- 131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT)
- Where
- 10 sites in Italy, United Kingdom
- Volunteers
- 32 people
- Sponsor
- Philogen S.p.A.
Locally Advanced Neuroendocrine Neoplasm, Metastatic Neuroendocrine Neoplasm
Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor
This phase III trial compares the effect of telotristat ethyl and the current standard of care somatostatin analog therapy or somatostatin analog therapy alone in treating patients with neuroendocrine tumor that has spread to…
- Trial name
- NCT04810091
- Testing
- Questionnaire Administration, Telotristat Ethyl
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- M.D. Anderson Cancer Center
Extrahepatic Bile Duct Cancer, Gastric Cancer
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells.
- Conditions
- Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer
- Trial name
- NCT00019474
- Testing
- filgrastim, recombinant interferon alfa, fluorouracil
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Montefiore Medical Center
Advanced Solid Tumor, Ovarian Cancer
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NUV-868-01 is a first-in human, open- label, Phase 1/2 dose escalation and expansion study in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer, Cancer of Ovary
- Trial name
- NCT05252390
- Testing
- NUV-868, Olaparib, Enzalutamide
- Where
- 22 sites in United States, Australia
- Volunteers
- 82 people
- Sponsor
- Nuvation Bio Inc.
Non-Small Cell Lung Cancer, Advanced Solid Tumor
Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
This is a multicenter, open label, first in human (FIH) study of inlexisertib as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in participants with advanced or metastatic solid tumors with RAS/MAPK…
- Conditions
- Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT04892017
- Testing
- Inlexisertib, Trametinib, Binimetinib
- Where
- 10 sites in United States
- Volunteers
- 91 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
P1b: Advanced Solid Tumors, P2: Biliary Tract Cancer
A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients
This study is a Phase 1b/2 multi-center study to assess the safety, tolerability, pharmacokinetics of CTX-009 (ABL001) in combination with Irinotecan or Paclitaxel in patients with advanced or metastatic solid tumors.
- Trial name
- NCT04492033
- Testing
- CTX-009 (ABL001), Paclitaxel, Irinotecan
- Where
- 4 sites in South Korea
- Volunteers
- 41 people
- Sponsor
- Handok Inc.
Solid Cancers, Solid Tumor Cancer
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
The goal of this study is to obtain safety, tolerability, PK, and preliminary clinical antitumor activity for XL495 as a single agent and in combination with select cytotoxic agents in participants with locally advanced or…
- Conditions
- Solid Cancers, Solid Tumor Cancer, Solid Tumor Malignancy, Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
- Trial name
- NCT06630247
- Testing
- XL495, ADC cytotoxic agents
- Where
- 10 sites in United States
- Volunteers
- 9 people
- Sponsor
- Exelixis
Malignant Salivary Gland Neoplasm, Recurrent Salivary Gland Carcinoma
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
This phase II trial is studying how well dasatinib works in treating patients with malignant salivary gland tumors that have come back after treatment or have spread to other parts of the body.
- Conditions
- Malignant Salivary Gland Neoplasm, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v7
- Trial name
- NCT00859937
- Testing
- Dasatinib, Laboratory Biomarker Analysis
- Where
- 34 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.